Literature DB >> 26059208

No benefit for regional control and survival by planned neck dissection in primary irradiated oropharyngeal cancer irrespective of p16 expression.

R Maquieira1, S K Haerle2, G F Huber3, A Soltermann4, S R Haile5,6, S J Stoeckli1, Martina A Broglie7.   

Abstract

The aim of the study was to assess regional control and survival in primary irradiated oropharyngeal cancer patients with advanced neck disease (≥cN2a) receiving planned neck dissection (PND) irrespective of the nodal response compared to salvage neck dissection (SND) in case of regional persistence or reccurence in relation to tumoral p16 overexpression. 96 consecutive patients treated at the University Hospital of Zurich, Switzerland were included. Tissue microarray-based scoring of p16 expression was obtained. 5 years overall (OS) and disease-specific survival (DSS) in the PND and SND cohort were 70 vs. 57 % (p = 0.20) and 80 vs. 65 % (p = 0.14), respectively. Regional control in PND and SND achieved 95 vs. 87 % (p = 0.29), respectively. There was no statistically significant impact of neck treatment (PND vs. SND) on regional control or survival among patients with p16-negative tumors (5 years OS 59 vs. 50 %, p = 0.66; 5 years DSS 59 vs. 57 %, p = 0.89) nor among patients with p16-positive tumors (5 years OS 84 vs. 67 %, p = 0.21; 5 years DSS 95 vs. 81 %, p = 0.24). The type of neck dissection after primary intensity-modulated radiotherapy (IMRT) had no impact on regional control and survival even in human papillomavirus (HPV)-associated disease. Therefore we are convinced that based on the accuracy of newer diagnostic modalities the surveillance of a radiologically negative neck after primary chemoradiation (CRT) is oncologically safe irrespective of p16 expression of the tumor.

Entities:  

Keywords:  Oropharyngeal squamous cell carcinoma; Planned neck dissection; Regional tumor control; Salvage neck dissection; Survival; p16 expression

Mesh:

Substances:

Year:  2015        PMID: 26059208     DOI: 10.1007/s00405-015-3675-9

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  56 in total

1.  Planned neck dissection after chemoradiotherapy in advanced oropharyngeal squamous cell cancer: the role of US, MRI and FDG-PET/TC scans to assess residual neck disease.

Authors:  Raul Pellini; Valentina Manciocco; Mario Turri-Zanoni; Antonello Vidiri; Giuseppe Sanguineti; Laura Marucci; Rosa Sciuto; Renato Covello; Isabella Sperduti; Ramy Kayal; Vincenzo Anelli; Barbara Pichi; Giuseppe Mercante; Giuseppe Spriano
Journal:  J Craniomaxillofac Surg       Date:  2014-07-09       Impact factor: 2.078

2.  Transoral robotic surgery and human papillomavirus status: Oncologic results.

Authors:  Marc A Cohen; Gregory S Weinstein; Bert W O'Malley; Michael Feldman; Harry Quon
Journal:  Head Neck       Date:  2010-12-06       Impact factor: 3.147

3.  High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma.

Authors:  Lisa Licitra; Federica Perrone; Paolo Bossi; Simona Suardi; Luigi Mariani; Raffaella Artusi; Maria Oggionni; Chiara Rossini; Giulio Cantù; Massimo Squadrelli; Pasquale Quattrone; Laura D Locati; Cristiana Bergamini; Patrizia Olmi; Marco A Pierotti; Silvana Pilotti
Journal:  J Clin Oncol       Date:  2006-12-20       Impact factor: 44.544

4.  Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.

Authors:  Carole Fakhry; Qiang Zhang; Phuc Felix Nguyen-Tan; David Rosenthal; Adel El-Naggar; Adam S Garden; Denis Soulieres; Andy Trotti; Vilija Avizonis; John Andrew Ridge; Jonathan Harris; Quynh-Thu Le; Maura Gillison
Journal:  J Clin Oncol       Date:  2014-06-23       Impact factor: 44.544

5.  Planned neck dissection after concomitant radiochemotherapy for advanced head and neck cancer.

Authors:  Douglas K Frank; Kenneth S Hu; Bruce E Culliney; Mark S Persky; Moses Nussbaum; Stimson P Schantz; Stephen C Malamud; Roy A Holliday; Azita S Khorsandi; Roy B Sessions; Louis B Harrison
Journal:  Laryngoscope       Date:  2005-06       Impact factor: 3.325

6.  Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer.

Authors:  Laura A Goguen; Marshall R Posner; Roy B Tishler; Lori J Wirth; Charles M Norris; Donald J Annino; Christopher A Sullivan; Yi Li; Robert I Haddad
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2006-05

7.  Human papillomavirus reduces the prognostic value of nodal involvement in tonsillar squamous cell carcinomas.

Authors:  Jos M J A A Straetmans; Nadine Olthof; Jeroen J Mooren; Jos de Jong; Ernst-Jan M Speel; Bernd Kremer
Journal:  Laryngoscope       Date:  2009-10       Impact factor: 3.325

8.  Management of the lymph node-positive neck in the patient with human papillomavirus-associated oropharyngeal cancer.

Authors:  Adam S Garden; Gary B Gunn; Amy Hessel; Beth M Beadle; Salmaan Ahmed; Adel K El-Naggar; Clifton D Fuller; Lauren A Byers; Jack Phan; Steven J Frank; William H Morrison; Merill S Kies; David I Rosenthal; Erich M Sturgis
Journal:  Cancer       Date:  2014-06-04       Impact factor: 6.860

Review 9.  Cystic metastasis from head and neck squamous cell cancer: a distinct disease variant?

Authors:  David Goldenberg; James Sciubba; Wayne M Koch
Journal:  Head Neck       Date:  2006-07       Impact factor: 3.147

10.  Postoperative IMRT in head and neck cancer.

Authors:  Gabriela Studer; Katrin Furrer; Bernard J Davis; Sandro S Stoeckli; Roger A Zwahlen; Urs M Luetolf; Christoph Glanzmann
Journal:  Radiat Oncol       Date:  2006-10-19       Impact factor: 3.481

View more
  1 in total

1.  Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.

Authors:  Saad Maqsood; Michael B Jameson; Charles De Groot; Cristian Hartopeanu; Nur Azri Bin Haji Mohd Yasin; Ziad Thotathil
Journal:  Cancer Rep (Hoboken)       Date:  2018-04-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.